Novo to acquire the genetics business of Benchmark Holdings for £260m.

Novo, a life sciences investor, agreed to acquire the genetics business of Benchmark Holdings, an aquaculture genetics, specialist nutrition, and health business, for £260m. "We are very pleased to announce plans to acquire the Benchmark genetics business from Benchmark Holdings. Both animal and plant genetics hold immense potential to transform the global food industry, enabling more efficient and sustainable ways to feed a growing population. In particular, advancements in aquaculture genetics, such as those in the salmon industry, present significant opportunities to improve productivity, resilience, and environmental outcomes," Aleks Engel, Novo Holdings Partner.